WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

ISSN 2457-0400

Impact Factor  :  5.464

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • WJAHR New Impact Factor

    Its our Pleasure to Inform you that WJAHR Impact Factor has been increased from  4.897 to 5.464 due to high quality Publication at International Level

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR December 2022 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • WJAHR: DECEMBER ISSUE PUBLISHED

    DECEMBER 2022 Issue has been successfully launched on 1 December 2022.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

HEPARIN-INDUCED THROMBOCYTOPENIA: A REVIEW OF THE CLASSIFICA-TION, DIAGNOSIS AND TREATMENT

Milena Viana de Queiroz*, Carolina Amorim Baptista Rocha, Michelle Nogueira de Oliveira, Jean Fialho Fazolo de Souza, Lais Chiesse Ribas and Maria Júlia Campos Guerra

ABSTRACT

Platelets comprise the blood plasma and are responsible for primary hemostasis that culminates in the formation of a platelet buffer. The standard value of the same in peripheral blood varies between 150,000 and 400,000 per cubic millimeter of blood. When this value becomes less than 150,000 per cubic millimeter of blood, thrombocy-topenia occurs. Several drugs can generate this condition, but mainly heparin. The present study aims to review the literature highlighting the importance of early diagnosis and adequate therapeutic management of heparin-induced thrombocytopenia (HIT). A literature review was conducted in the electronic databases SciELO, LILACS and MEDLINE, between 2001 and 2018, using the descriptors thrombocytopenia, heparin, diagnosis and treat-ment. The HIT can be classified as type I and II, and type I is a non-immune thrombocytopenia related to a transi-ent and benign reduction in the number of platelets per platelet aggregation and type II HIT occurs due to an im-mune reaction of type II hypersensitivity. The most common complications of HIT type II are venous thrombo-embolism, especially venous thrombosis and pulmonary embolism. The diagnosis should be raised in any patient with thrombocytopenia or thrombosis in confirming the use of this drug. Immediate discontinuation of heparin is mandatory in the face of clinical suspicion of HIT associated with anticoagulant therapy not heparin. In view of the above, it is concluded that the HIT mainly affects surgical patients who use heparin for more than four days for the prophylaxis of thromboembolic events. For this reason, if there is suspicion of HIT, early suspending the drug is mandatory, besides associating the non-heparin anticoagulation regimen.

[Full Text Article]